Phase IV study of retention on fingolimod <i>versus</i> injectable multiple sclerosis therapies: a randomized clinical trial.

Ther Adv Neurol Disord · 2018 · PMC5964857 · PMID 29844796

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

Annualized relapse rates There was a nonsignificant trend towards lower annualized relapse rate (ARR) among patients on fingolimod, with a rate 30% lower than those on iDMTs [fingolimod ARR, 0.22; iDMT ARR, 0.31; ARR ratio (95% CI), 0.70 (0.47–1.05); p = 0.084; Figure 3(a) ].

also in 5,406 other papers

highly significantno p-value reported

To address this, a sensitivity analysis excluded patients who switched treatment between weeks 11 and 16, and found that the retention rate with iDMT increased to 41.4%, but the between-group difference in retention relative to fingolimod remained highly significant.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.